06 February 2024 Radiopharm’s Pan-Cancer Targeting Monoclonal Antibody DUNP19 (RAD 502) halts tumor progression and prolongs survival in various cancer models 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post